Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77219 | 0.71 | — | — | |
| SCHEMBL25857731 | 0.70 | — | — | |
| SCHEMBL19021920 | 0.67 | — | — | |
| SCHEMBL10110813 | 0.67 | — | — | |
| SCHEMBL25857729 | 0.65 | — | — | |
| SCHEMBL25857726 | 0.65 | — | — | |
| SCHEMBL25857683 | 0.64 | — | — | |
| SCHEMBL25857698 | 0.64 | CA12 (0.44) | CA12CA1CA2CA9 | |
| SCHEMBL26040797 | 0.64 | — | — | |
| SCHEMBL25857733 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230265100-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-20230159465-A1 | IMMUNOMODULATOR | HITGEN INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159465-A1 | IMMUNOMODULATOR | HITGEN INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230147458-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130217666-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | GENENTECH, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110288078-A1 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2007076348-A2 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159465-A1 | IMMUNOMODULATOR | IL2, IL17A, IL2RA | CA12 2711/4885CA1 3066/4885CA2 4528/4885 |
| US-20230147458-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | CA12 3966/4885CA1 4430/4885CA2 4099/4885 |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | TSLP, IL5, CMA1 | CA12 1713/4885CA1 1902/4885CA2 811/4885 |
| US-20230227437-A1 | IMMUNOMODULATOR | IL17A, IL2, IL2RA | CA12 3293/4885CA1 3418/4885CA2 4362/4885 |
| US-20230265100-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | CA12 4755/4885CA1 4314/4885CA2 4376/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | CA12 4365/4885CA1 4571/4885CA2 3989/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | CA12 1611/4885CA1 1227/4885CA2 381/4885 |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ABL1, CDKN1A, MAP3K13 | CA12 3577/4885CA1 3716/4885CA2 3440/4885 |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | CA12 3966/4885CA1 4430/4885CA2 4099/4885 |
| US-20130217666-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | NFKB1, NFKBIA, RELA | CA12 4457/4885CA1 4219/4885CA2 3755/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | CA12 1708/4885CA1 1476/4885CA2 444/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | CA12 3093/4885CA1 2386/4885CA2 4447/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | CA12 1217/4885CA1 3054/4885CA2 4296/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | CA12 1708/4885CA1 1476/4885CA2 444/4885 |
| US-20110288078-A1 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | CA12 4737/4885CA1 4808/4885CA2 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.